RxDoctor Payments Data

Rashmi Benda, MD

Radiation Oncology · Woonsocket, RINPI 1750334769

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Zap Surgical Systems, Inc. at 24.8% of the total. Reporting peaked in 2019 at $389 and has fallen 82.4% since, to $69 in 2024.

$802in general payments, 2019–2025

Across 12 payments — averaging $66.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zap Surgical Systems, Inc.$199
  • Siemens Medical Solutions USA, Inc.$195
  • Puma Biotechnology, Inc.$99
  • Progenics Pharmaceuticals, Inc.$81
  • Novartis$69
  • Eisai Inc.$69
  • plus $90 from 3 others
$18,115in research payments, 2019–2025

Across 5 payments — averaging $3623.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$18K

What the payments were for

  • Food & beverage$802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Zap Surgical Systems, Inc.1$199
Siemens Medical Solutions USA, Inc.3$195
Puma Biotechnology, Inc.1$99
Progenics Pharmaceuticals, Inc.1$81
Novartis1$69
Eisai Inc.1$69
Accuray Incorporated2$40
Varian Medical Systems, Inc.1$34
Fortovia Therapeutics, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$802 in reported general payments places this provider in the 85th percentile of 26 radiation oncology providers in Rhode Island.

See all radiation oncology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$285,332
Medicare patients
282
Services billed
3,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl19$120

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Woonsocket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →